Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):405–408. doi: 10.1038/bjc.1992.82

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

E F Smit 1, H H Berendsen 1, D A Piers 1, J Smeets 1, A Riva 1, P E Postmus 1
PMCID: PMC1977612  PMID: 1313691

Abstract

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study of high-dose EPI as initial treatment for patients with advanced non-small cell lung cancer (NSCLC) (stage III and IV). Between May 1988 and November 1989, 25 patients were entered. The starting dose of EPI was 135 mg m-2, with dose attenuations and escalations of 15 mg m-2 based on mid-cycle evaluation of toxicity. Treatment was repeated every 3 weeks. Nine partial responses (36%, 95% CI: 18-57.5%) and 11 patients with disease stabilisation (44%) were observed. Median (range) time to progression was 19 (3-70) weeks. Median (range) survival is 32 (9-116+) weeks. There were no treatment related deaths. Major side effects were leukocytopenia WHO grade III/IV (23% of courses) and mucositis WHO grade II/III (15% of courses). In two patients left ventricular ejection fraction decreased greater than 15% compared to baseline values after a cumulative Epirubicin dose of 435 mg m-2, and therefore went off study. In none of the patients clinical signs of congestive heart failure were observed. We conclude from our data that high-dose EPI, contrary to previous negative studies using lower doses of EPI, ranks amongst the most active regimens against advanced NSCLC. Toxicity of high-dose EPI is moderate. Further evaluation of this compound in combination regimens is recommended.

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Case D. C., Jr, Ervin T. J., Gams R., Sonneborn H. L., Paul S. D., Oldham F. B. Phase I-II study of epirubicin in multiple myeloma. Cancer Res. 1988 Nov 1;48(21):6246–6248. [PubMed] [Google Scholar]
  2. Case D. C., Jr, Gams R., Ervin T. J., Boyd M. A., Oldham F. B. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Cancer Res. 1987 Dec 1;47(23):6393–6396. [PubMed] [Google Scholar]
  3. Cersosimo R. J., Hong W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425–439. doi: 10.1200/JCO.1986.4.3.425. [DOI] [PubMed] [Google Scholar]
  4. Cortes E. P., Holland J. F., Glidewell O. Amputation and adriamycin in primary osteosarcoma: a 5-year report. Cancer Treat Rep. 1978 Feb;62(2):271–277. [PubMed] [Google Scholar]
  5. Ferrazzi E., Nicoletto O., Vinante O., Pagnin P., Maraglino G., Ganzina F., Fiorentino M. V. Phase II study of 4'epi-doxorubicin. Tumori. 1982 Oct 31;68(5):431–435. doi: 10.1177/030089168206800513. [DOI] [PubMed] [Google Scholar]
  6. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  7. Jones R. B., Holland J. F., Bhardwaj S., Norton L., Wilfinger C., Strashun A. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol. 1987 Feb;5(2):172–177. doi: 10.1200/JCO.1987.5.2.172. [DOI] [PubMed] [Google Scholar]
  8. Luedke D. W., Einhorn L., Omura G. A., Sarma P. R., Bartolucci A. A., Birch R., Greco F. A. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990 May;8(5):886–891. doi: 10.1200/JCO.1990.8.5.886. [DOI] [PubMed] [Google Scholar]
  9. Nielsen D., Jensen J. B., Dombernowsky P., Munck O., Fogh J., Brynjolf I., Havsteen H., Hansen M. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990 Nov;8(11):1806–1810. doi: 10.1200/JCO.1990.8.11.1806. [DOI] [PubMed] [Google Scholar]
  10. Preisler H. D., Gessner T., Azarnia N., Bolanowska W., Epstein J., Early A. P., D'Arrigo P., Vogler R., Winton L., Chervenik P. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol. 1984;12(2):125–130. doi: 10.1007/BF00254604. [DOI] [PubMed] [Google Scholar]
  11. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  12. Razek A., Valeriote F., Vietti T. Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res. 1972 Jul;32(7):1496–1500. [PubMed] [Google Scholar]
  13. Rozencweig M., ten Bokkel Huinink W., Cavalli F., Bruntsch U., Dombernowsky P., Høst H., Bramwell V., Renard G., Van Glabbeke M., Decoster G. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. J Clin Oncol. 1984 Apr;2(4):275–281. doi: 10.1200/JCO.1984.2.4.275. [DOI] [PubMed] [Google Scholar]
  14. Tjuljandin S. A., Doig R. G., Sobol M. M., Watson D. M., Sheridan W. P., Morstyn G., Mihaly G., Green M. D. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res. 1990 Aug 15;50(16):5095–5101. [PubMed] [Google Scholar]
  15. Torti F. M., Bristow M. M., Lum B. L., Carter S. K., Howes A. E., Aston D. A., Brown B. W., Jr, Hannigan J. F., Jr, Meyers F. J., Mitchell E. P. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986 Jul;46(7):3722–3727. [PubMed] [Google Scholar]
  16. Wheeler R. H., Ensminger W. D., Thrall J. H., Anderson J. L. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Cancer Treat Rep. 1982 Mar;66(3):493–498. [PubMed] [Google Scholar]
  17. Wils J. A. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma. Invest New Drugs. 1984;2(4):397–399. doi: 10.1007/BF00171592. [DOI] [PubMed] [Google Scholar]
  18. Woods R. L., Williams C. J., Levi J., Page J., Bell D., Byrne M., Kerestes Z. L. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990 Apr;61(4):608–611. doi: 10.1038/bjc.1990.135. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES